RETRACTED: LncRNA TLR8-AS1 suppresses miR-34a maturation in hepatocellular carcinoma to suppress cell proliferation and migration (Retracted article. See JUN, 2023)

被引：2

作者：

Shi, Xin ^{[1
]}

Chen, Hu ^{[1
]}

Wang, Wei ^{[1
]}

Yan, Bingzheng ^{[1
]}

Yang, Zhikai ^{[1
]}

Zhang, Jingpo ^{[1
]}

机构：

[1] Hebei Med Univ, Dept Hepatobiliary Surg, First Hosp, 89 Donggang Rd, Shijiazhuang 050000, Hebei, Peoples R China

来源：

MAMMALIAN GENOME | 2021年 / 32卷 / 06期

关键词：

LIVER-CANCER; HEPATITIS-B; EXPRESSION; MORTALITY; MECHANISM; SURVIVAL; CHINA;

D O I：

10.1007/s00335-021-09920-1

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

TLR8-AS1 has been characterized as an oncogenic lncRNA in ovarian cancer, while its role in hepatocellular carcinoma (HCC) is unknown. This study aimed to explore the role of TLR8-AS1 in HCC. TLR8-AS1 expression in HCC and paired non-tumor tissues from 62 HCC patients was determined by RT-qPCR. The prognostic value of TLR8-AS1 for HCC was analyzed by performing a 5-year follow-up. Correlations between TLR8-AS1 and mature miR-34a and miR-34a precursor were analyzed by Pearson's correlation coefficient. The roles of TLR8-AS1 and miR-34a in regulating the proliferation and migration were explored by CCK-8 assay and Transwell migration assay. We found that TLR8-AS1 was upregulated in HCC and predicted poor survival. Across HCC tissues, TLR8-AS1 was inversely correlated with mature miR-34a, but not miR-34a precursor. In HCC cells, TLR8-AS1 overexpression downregulated mature miR-34a, but not miR-34a precursor. Cell proliferation and Transwell migration assay showed that TLR8-AS1 overexpression reduced the enhancing effects of miR-34a on cell proliferation and migration. TLR8-AS1 may suppress miR-34a maturation in HCC to suppress cell proliferation and migration.

引用

页码：530 / 536

页数：7

共 17 条

[1] Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Altekruse, Sean F.
Henley, S. Jane
Cucinelli, James E.
McGlynn, Katherine A.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) : 542 - 553
[2] Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design
Burrel, Marta
Reig, Maria
Forner, Alejandro
Barrufet, Marta
Rodriguez de Lope, Carlos
Tremosini, Silvia
Ayuso, Carmen
Llovet, Josep M.
Isabel Real, Maria
Bruix, Jordi
[J]. JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1330 - 1335
[3] Cancer incidence and mortality in China in 2013: an analysis based on urbanization level
Chen, Wanqing
Zheng, Rongshou
Zhang, Siwei
Zeng, Hongmei
Zuo, Tingting
Xia, Changfa
Yang, Zhixun
He, Jie
[J]. CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (01) : 1 - 10
[4] Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma A 20-Year Experience
Fan, Sheung Tat
Lo, Chung Mau
Poon, Ronnie T. P.
Yeung, Chun
Liu, Chi Leung
Yuen, Wai Key
Lam, Chi Ming
Ng, Kelvin K. C.
Chan, See Ching
[J]. ANNALS OF SURGERY, 2011, 253 (04) : 745 - 758
[5] Precision diagnosis and treatment of liver cancer in China
Fu, Jing
Wang, Hongyang
[J]. CANCER LETTERS, 2018, 412 : 283 - 288
[6] The role of microRNAs in liver cancer progression
Huang, S.
He, X.
[J]. BRITISH JOURNAL OF CANCER, 2011, 104 (02) : 235 - 240
[7] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]
[8] Llerena Susana, 2018, Oncotarget, V9, P30869, DOI 10.18632/oncotarget.25766
[9] Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide
Maucort-Boulch, Delphine
de Martel, Catherine
Franceschi, Silvia
Plummer, Martyn
[J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (12) : 2471 - 2477
[10] Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
Momin, Behnoosh R.
Pinheiro, Paulo S.
Carreira, Helena
Li, Chunyu
Weir, Hannah K.
[J]. CANCER, 2017, 123 : 5059 - 5078

← 1 2 →